What is Talzenna and what is it used for?
Talzenna contains the active substance talazoparib. It is a type of anticancer medicine known as a ‘PARP (poly-ADP ribose polymerase) inhibitor’. Talzenna works by blocking PARP, which is an enzyme that repairs damaged DNA in certain cancer cells. As a result, the cancer cells can no longer repair themselves and they die.

Talzenna is a medicine used:

• Alone to treat adults with breast cancer of a type known as HER2-negative breast cancer who have an abnormal inherited BRCA gene.
• In combination with a medicine called enzalutamide, to treat adults with prostate cancer who no longer respond to a hormone therapy or surgical treatment to lower testosterone.

The medicine can only be obtained with a prescription.


Reference Information
If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Talzenna visit the electronic Medicines Compendium (eMC).

▼ This medicine is subject to additional monitoring.

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.